We shall discuss the alterations and the well-established renoprotective impact of the ACE2/Ang-(1-7)/MasR axis, attenuating the progression of CKD, and with the same rationale describe preliminary animal studies indicating that the stimulation of the ACE2/Ang-(1-7)/MasR axis may serve as a novel therapeutic option in COVID-19 patients, with special focus on the management of evolving AKI. Here, ACE2 is linked to COVID-19.